Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm trial of trastuzumab deruxtecan in HER2-positive unresectable or metastatic gastric/GEJ adenocarcinoma after trastuzumab
2019-001512-34Phase 2Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Confirmed objective response rate (ORR). Started Jul 2019; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2019-001512-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001512-34.